While CD133-overexpressing MIC cells displayed increased cell viability and a reduced apoptotic response to trametinib, CRISPR-Cas9 knockout of CD133 reversed this phenotype in different melanoma cell lines, re-sensitizing cells to trametinib. Here, PROM1 is linked to melanoma.